

Georg Karpel-Massler

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1550512/georg-karpel-massler-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66 papers	1,617 citations	25 h-index	38 g-index
71 ext. papers	1,975 ext. citations	5.8 avg, IF	4.63 L-index

#	Paper	IF	Citations
66	Methodological Approaches for Assessing Metabolomic Changes in Glioblastomas.. <i>Methods in Molecular Biology</i> , 2022 , 2445, 305-328	1.4	1
65	Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma.. <i>Clinical Cancer Research</i> , 2022 , OF1-OF15	12.9	2
64	MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen. <i>Cancers</i> , 2022 , 14, 2563	6.6	1
63	In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma.. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	3
62	ONC201/TIC10 Is Empowered by 2-Deoxyglucose and Causes Metabolic Reprogramming in Medulloblastoma Cells Independent of C-Myc Expression.. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 734699	5.7	0
61	Block of Voltage-Gated Sodium Channels as a Potential Novel Anti-cancer Mechanism of TIC10. <i>Frontiers in Pharmacology</i> , 2021 , 12, 737637	5.6	1
60	A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab075	0.9	8
59	Targeting super-enhancers reprograms glioblastoma central carbon metabolism. <i>Oncotarget</i> , 2021 , 12, 1309-1313	3.3	0
58	Current state and future perspective of drug repurposing in malignant glioma. <i>Seminars in Cancer Biology</i> , 2021 , 68, 92-104	12.7	18
57	Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma. <i>Cancers</i> , 2021 , 13,	6.6	1
56	Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma. <i>Nature Communications</i> , 2021 , 12, 5203	17.4	4
55	The limitations of targeting MEK signalling in Glioblastoma therapy. <i>Scientific Reports</i> , 2020 , 10, 7401	4.9	4
54	Considering the Experimental use of Temozolomide in Glioblastoma Research. <i>Biomedicines</i> , 2020 , 8,	4.8	11
53	Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma. <i>British Journal of Cancer</i> , 2020 , 122, 1146-1157	8.7	19
52	A New Treatment Opportunity for DIPG and Diffuse Midline Gliomas: 5-ALA Augmented Irradiation, the 5aai Regimen. <i>Brain Sciences</i> , 2020 , 10,	3.4	2
51	Comment in Response to "Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy etc. by B. Kaina". <i>Biomedicines</i> , 2020 , 8,	4.8	3
50	HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. <i>Journal of Clinical Investigation</i> , 2020 , 130, 3699-3716	15.9	41

49	Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems. <i>Cells</i> , 2020 , 9,	7.9	9
48	Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma. <i>Cancers</i> , 2020 , 12,	6.6	11
47	Rare Case of Sporadic Malignant Optic Pathway Glioma in 71-Year-Old Woman. <i>World Neurosurgery</i> , 2020 , 133, 413-415	2.1	2
46	Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. <i>Biomedicines</i> , 2019 , 7,	4.8	69
45	Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma. <i>British Journal of Pharmacology</i> , 2019 , 176, 3681-3694	8.6	18
44	Activation of LXR Receptors and Inhibition of TRAP1 Causes Synthetic Lethality in Solid Tumors. <i>Cancers</i> , 2019 , 11,	6.6	12
43	Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis. <i>Cellular Oncology (Dordrecht)</i> , 2019 , 42, 287-301	7.2	10
42	Compare and contrast: pediatric cancer versus adult malignancies. <i>Cancer and Metastasis Reviews</i> , 2019 , 38, 673-682	9.6	20
41	Cell death-based treatment of childhood cancer. <i>Cell Death and Disease</i> , 2018 , 9, 116	9.8	9
40	Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. <i>Clinical Cancer Research</i> , 2018 , 24, 5392-5406	12.9	43
39	Augmentation of 5-Aminolevulinic Acid Treatment of Glioblastoma by Adding Ciprofloxacin, Deferiprone, 5-Fluorouracil and Febuxostat: The CAALA Regimen. <i>Brain Sciences</i> , 2018 , 8,	3.4	12
38	Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells. <i>International Journal of Oncology</i> , 2018 , 53, 1881-1896	4.4	7
37	Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma. <i>Clinical Cancer Research</i> , 2018 , 24, 3941-3954	12.9	25
36	Simultaneous Interference with HER1/EGFR and RAC1 Signaling Drives Cytostasis and Suppression of Survivin in Human Glioma Cells in Vitro. <i>Neurochemical Research</i> , 2017 , 42, 1543-1554	4.6	9
35	Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. <i>Cancer Research</i> , 2017 , 77, 3513-3526	10.1	45
34	Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. <i>Nature Communications</i> , 2017 , 8, 1067	17.4	73
33	The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy. <i>Breast Cancer: Targets and Therapy</i> , 2017 , 9, 495-514	3.9	7
32	Anti-glioma Activity of Dapsone and Its Enhancement by Synthetic Chemical Modification. <i>Neurochemical Research</i> , 2017 , 42, 3382-3389	4.6	22

31	Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma. <i>Expert Opinion on Drug Discovery</i> , 2017 , 12, 1031-1040	6.2	27
30	The effects of PI3K-mediated signalling on glioblastoma cell behaviour. <i>Oncogenesis</i> , 2017 , 6, 398	6.6	24
29	EXTH-79. INITIAL EXPERIENCES WITH COMPASSIONATE-USE CUSP9v3/v4 FOR RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2017 , 19, vi90-vi90	1	3
28	Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma. <i>Oncotarget</i> , 2017 , 8, 37140-37153	3.3	22
27	BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma. <i>Oncotarget</i> , 2017 , 8, 29558-29573	3.3	22
26	Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen. <i>Oncotarget</i> , 2017 , 8, 60727-60749	3.3	22
25	Cell Death Induction in Cancer Therapy - Past, Present, and Future. <i>Critical Reviews in Oncogenesis</i> , 2016 , 21, 253-267	1.3	15
24	Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo. <i>Oncotarget</i> , 2016 , 7, 33512-28	3.3	37
23	Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo. <i>Oncotarget</i> , 2016 , 7, 12791-805	3.3	33
22	A paired comparison between glioblastoma "stem cells" and differentiated cells. <i>International Journal of Cancer</i> , 2016 , 138, 1709-18	7.5	34
21	A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers. <i>Clinical Cancer Research</i> , 2016 , 22, 4698-711	12.9	52
20	Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect. <i>Journal of Neuro-Oncology</i> , 2015 , 122, 21-33	4.8	36
19	TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo. <i>Oncotarget</i> , 2015 , 6, 36456-71	3.3	48
18	A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy. <i>PLoS ONE</i> , 2015 , 10, e0131670	3.7	28
17	RIST: a potent new combination therapy for glioblastoma. <i>International Journal of Cancer</i> , 2015 , 136, E173-87	7.5	35
16	Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo. <i>Oncotarget</i> , 2015 , 6, 14507-21	3.3	42
15	Killing me softly--future challenges in apoptosis research. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 3746-67	6.3	24
14	A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy. <i>Molecular and Cellular Therapies</i> , 2014 , 2, 32		33

13	PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma. <i>PLoS ONE</i> , 2014 , 9, e114583	3.7	37
12	CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. <i>Oncotarget</i> , 2014 , 5, 8052-82	3.3	81
11	Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014 , 14, 313-8	2.2	32
10	Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1783-95	6.1	47
9	Inhibition of NF- κ B signaling ablates the invasive phenotype of glioblastoma. <i>Molecular Cancer Research</i> , 2013 , 11, 1611-23	6.6	51
8	A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. <i>Oncotarget</i> , 2013 , 4, 502-30	3.3	131
7	Why dapsone stops seizures and may stop neutrophils delivery of VEGF to glioblastoma. <i>British Journal of Neurosurgery</i> , 2012 , 26, 813-7	1	18
6	Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma. <i>Cancers</i> , 2012 , 4, 523-30	6.6	20
5	Drug combinations enhancing the antineoplastic effects of erlotinib in high-grade glioma. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2011 , 6, 384-94	2.6	2
4	Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?. <i>British Journal of Pharmacology</i> , 2011 , 164, 1393-6	8.6	14
3	Erlotinib in glioblastoma: lost in translation?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2011 , 11, 748-55	2.2	16
2	Ribozyme-mediated inhibition of 801-bp deletion-mutant epidermal growth factor receptor mRNA expression in glioblastoma multiforme. <i>Molecules</i> , 2010 , 15, 4670-8	4.8	4
1	Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?. <i>Molecular Cancer Research</i> , 2009 , 7, 1000-12	6.6	93